Memorial Sloan-Kettering
They hope the website will be an unbiased source for genetic risk information, testing, and financial support services and spur cascade testing in families.
FDA Recognizes Portion of MSK Oncology Knowledge Base in Public Human Genetic Variant Database
MSK's OncoKB is the first collection of somatic variants that the FDA has accepted for test developers to use in premarket validation studies.
GNS Healthcare Joins Memorial Sloan Kettering Innovation Hub for Precision Oncology
The collaboration uses virtual patients built with multiomic and clinical data to identify aggressive disease subtypes and discover new drug targets.
TERT promoter mutations could help predict recurrence, guide treatment decisions, and be a target for precision oncology drugs, according to a new study.
SpringWorks, MSK Collaborate to Study MEK Inhibitor in Certain Solid TumorsÂ
The partners will explore the activity of mirdametinib with fulvestrant in breast cancer patients with MAPK alterations and as a single agent in other MAPK-altered solid tumors.